3 days Ago By ABMN Staff
Zions Bancorporation N.A. decreased its position in IQVIA Holdings Inc.
( NYSE:IQV – Free Report ) by 44.2% during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 148 shares of the medical research company’s stock after selling 117 shares during the period.
Zions Bancorporation N.A.’s holdings in IQVIA were worth $31,000 as of its most recent filing with the SEC.
Several other hedge funds also recently made changes to their positions in the business. Versant Capital Management Inc boosted its holdings in IQVIA by 733.3% during the second quarter.
Versant Capital Management Inc now owns 125 shares of the medical research company’s stock worth $26,000 after purchasing an additional 110 shares during the last quarter. Opal Wealth Advisors LLC acquired a new position in shares of IQVIA during the 2nd quarter worth about $27,000. Rise Advisors LLC bought a new position in shares of IQVIA in the 1st quarter valued at about $31,000.
Riverview Trust Co bought a new stake in IQVIA during the first quarter worth about $32,000. Finally, International Assets Investment Management LLC acquired a new position in IQVIA during the second quarter valued at approximately $32,000. 89.
62% of the stock is owned by institutional investors. Insider Transactions at IQVIA In related news, insider Eric Sherbet sold 1,300 shares of the business’s stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $246.
33, for a total value of $320,229.00. Following the completion of the sale, the insider now directly owns 19,536 shares in the company, valued at $4,812,302.
88. The sale was disclosed in a filing with the SEC, which is available at this link . Insiders own 1.
60% of the company’s stock. IQVIA Stock Performance IQVIA ( NYSE:IQV – Get Free Report ) last released its quarterly earnings results on Monday, July 22nd. The medical research company reported $2.
64 EPS for the quarter, beating the consensus estimate of $2.57 by $0.07.
IQVIA had a net margin of 9.39% and a return on equity of 28.59%.
The business had revenue of $3.81 billion for the quarter, compared to the consensus estimate of $3.79 billion.
During the same period in the prior year, the company posted $2.22 earnings per share. IQVIA’s revenue was up 2.
3% compared to the same quarter last year. Research analysts expect that IQVIA Holdings Inc. will post 10.
25 EPS for the current year. Analysts Set New Price Targets IQV has been the topic of a number of analyst reports. Royal Bank of Canada initiated coverage on IQVIA in a research note on Wednesday, September 4th.
They set an “outperform” rating and a $275.00 price objective on the stock. Barclays increased their price target on shares of IQVIA from $255.
00 to $275.00 and gave the company an “overweight” rating in a research note on Tuesday, July 23rd. UBS Group upped their target price on shares of IQVIA from $295.
00 to $300.00 and gave the company a “buy” rating in a report on Tuesday, July 23rd. Truist Financial lifted their price target on IQVIA from $292.
00 to $300.00 and gave the stock a “buy” rating in a report on Tuesday, July 23rd. Finally, The Goldman Sachs Group assumed coverage on IQVIA in a research note on Thursday, June 6th.
They issued a “buy” rating and a $270.00 price objective on the stock. Four equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company.
According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $266.67. Read Our Latest Stock Report on IQVIA About IQVIA ( Free Report ) IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.
It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. Read More Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter .
.
